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Background: Korean Red Ginseng (KRG) is a well-known natural product with anticarcinogenic and
antioxidant effects. We evaluated the antifatigue effect of KRG in patients with nonalcoholic fatty liver
disease (NAFLD).
Methods: Eighty patients with NAFLD were prospectively randomized to receive 3 wk of KRG or placebo
in addition to counseling on healthy eating and regular exercise. Liver function test, proinﬂammatory
cytokines, adiponectin, antioxidant activity, and fatigue score were measured and compared according to
the body mass index between the KRG and placebo groups.
Results: The liver function tests were signiﬁcantly improved after 3 wk of treatment in both groups. The
mean levels (at baseline and after treatment) of tumor necrosis factor-a were 108.0 pg/mL  54.8 pg/mL
and 92.7 pg/mL  39.0 pg/mL (p ¼ 0.018) in the KRG group and 123.1 pg/mL  42.1 pg/mL and 127.5 pg/
mL  62.2 pg/mL (p ¼ 0.694) in the placebo group, respectively. There was a signiﬁcant difference in
change of adiponectin levels between the KRG (7,751.2 pg/mL  3,108.1 pg/mL and 8,197.3 pg/
mL  2,714.5 pg/mL) and placebo groups (7,711.6 pg/mL  3,041.3 pg/mL and 7,286.1 pg/mL  5,188.7 pg/
mL, p ¼ 0.027). In patients with overweight, the fatigue score was signiﬁcantly decreased in the KRG
group (35.0  13.2 and 24.5  8.9, p ¼ 0.019).
Conclusion: Our results show that KRG might be effective in reducing proinﬂammatory cytokine and
fatigue in overweight patients with NAFLD, in addition to improvements in adiponectin levels.
Copyright  2015, The Korean Society of Ginseng, Published by Elsevier. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Fatty liver is deﬁned as a condition in which triglycerides
accumulate in hepatocytes to the extent that they comprise over 5%
of the mass of the liver. It is divided into alcoholic fatty liver disease
and nonalcoholic fatty liver disease (NAFLD) [1,2]. NAFLD and
nonalcoholic steatohepatitis are major global public healthedicine, Hallym University Chunc
331589 (http://clinicaltrials.gov/ct2
tudy.
ht  2015, The Korean Society of G
d/4.0/).problems, because they are related to insulin resistance, obesity,
and metabolic syndrome [3]. Most NAFLD patients show chronic
fatigue with peripheral inﬂammation and immune activation,
which causes serious social, economic, or medical problems and
impairs physical function [4,5].
The World Health Organization deﬁnes being overweight as
having a body mass index (BMI) of 25 kg/m2 or more, whereas aheon Sacred Heart Hospital, Hallym University College of Medicine, Sakju-ro 77,
/show/NCT02331589).
inseng, Published by Elsevier. This is an open access article under the CC BY-NC-ND
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overweight or obese signiﬁcantly increases the risk of developing
metabolic syndrome and liver disease [6]. In Western countries,
20e30% of NAFLD patients develop hepatocellular carcinoma [7].
Many overweight patients have been found to suffer from excessive
daytime sleepiness [8]. Ginseng (Panax ginseng Meyer) root has
beenwidely used as an herbal treatment in East Asia for more than
2,000 yr. Several studies have demonstrated that ginseng has
anticarcinogenic, anti-inﬂammatory, and antioxidant activities,
which were associated with fatigue syndrome [9,10].
Ginsenoside Rb1, the most abundant ginsenoside in the herb,
activates 50-adenosine monophosphate-activated protein kinase,
which suppresses the expression of genes that encode lipogenesis-
inducing enzymes in rats with fatty liver disease [11]. Moreover,
ginseng has been used to treat cancer-related fatigue without sig-
niﬁcant side effects [12]. Based on these ﬁndings, it is conceivable
that ginseng might contribute to reduce fatigue by modulating
inﬂammation and signal pathway in NAFLD patients. Some studies
have demonstrated the antifatigue effect of ginseng [13,14]. How-
ever, few studies have evaluatedwhether ginseng has a direct effect
on fatigue resulting from liver disease or on the biomarker of liver
disease. Therefore, in this study, we evaluated the anti-
inﬂammatory antioxidant, and antifatigue activities of Korean Red
Ginseng (KRG) in patients with NAFLD.2. Materials and methods
2.1. Patients
Between April 2011 and August 2012, we conducted a single-
blind, randomized, controlled clinical trial evaluating the efﬁcacy
of KRG (trial registration number: NCT02331589; http://
clinicaltrials.gov/ct2/show/NCT02331589). Patients aged over 20
yr and with aspartate aminotransferase (AST) or alanine amino-
transferase (ALT) levels of 50 IU/L or more were enrolled. Patients
who had viral hepatitis, alcoholic hepatitis, autoimmune hepatitis,
pancreatitis, hemochromatosis, Wilson’s disease, drug-induced
liver injury, or cancers were excluded. The study protocol con-
formed to the ethical guidelines of the 1975 Helsinki Declaration as
reﬂected by a priori approval of the Institutional Review Board for
Human Research in all participating hospitals. Informed consent for
study participation was obtained from each patient.Fig. 1. Flow chart for enrollment. ALT, alanine aminotransferase;Randomization was performed using a computerized proce-
dure.A total of 80 patients were enrolled. Among them, 14 patients
(5 patients in the KRG group and 9 patients in the placebo group)
were excluded (8 patients refused to participate, 4 patients had
inadequate records, and 2 patients were consuming alcohol; Fig. 1).
The levels of liver enzymes, proinﬂammatory cytokines [tumor
necrosis factor-a (TNF-a) and interleukin-6 (IL-6)], adiponectin,
antioxidant activity, and fatigue severity score were measured at
the beginning of the study (baseline) and after 3 wk of medication
(Fig. 2). We performed subgroup analysis by dividing the over-
weight and normal groups by BMI, because a previous report
suggested that obesity was closely associated with fatigue [15].
We conducted a baseline evaluation, which included obtaining
data for the following: family history, BMI, abdominal ultrasound
results, a complete blood count, a liver function test, and viral
markers. Serum biochemical parameters included total bilirubin
(TB), ALT, AST, gamma-glutamyl transpeptidase (g-GT), alkaline
phosphatase (ALP), lactate dehydrogenase (LDH), albumin, blood
urea nitrogen, a1-antitrypsin, creatinine, a-fetoprotein, prothrom-
bin time, blood glucose, triglycerides, total protein (TP), and total
cholesterol. All patients were tested for several hepatitis viruses
and human immunodeﬁciency virus. Hepatitis A virus was detected
using antihepatitis A IgG and IgM antibodies, and hepatitis B virus
was detected using the IgM antibody against the hepatitis B core
antigen, the hepatitis B surface antigen, and the hepatitis B surface
antibody. Hepatitis E virus was detected using antihepatitis E IgG
and IgM antibodies, and hepatitis C virus was detected using
antihepatitis C antibodies with or without the presence of hepatitis
C RNA.
2.2. Medical treatment
All patients were treated with Silybum marianum (Legalon,
Bukwang Pharmaceutical, Co., Ltd., Seoul, South Korea) capsule
(450 mg/d) and all patients were advised by the same clinician
(K.T.S.) to perform regular aerobic exercise for more than 30 min/d.
In addition, all patients also received counseling on healthy eating.
Patients who met the inclusion criteria were randomly assigned to
receive a KRG capsule (ginsenosides Rg1 þ Rb1 6.0 mg/g; 3,000
mg/d) or a placebo three times a day for 3 wk (Fig. 2). No other
medicationwas prescribed. The placebos weremanufactured at the
Korea Ginseng Corporation (Seoul, South Korea), and resembled the
KRG capsule powder in both shape and size.AST, aspartate aminotransferase; KRG, Korean Red Ginseng.
Fig. 2. Study design. IL-6, interleukin-6; KRG, Korean Red Ginseng; TNF-a, tumor necrosis factor-a.
Table 1
Clinical characteristics of patients
Variables All patients (n ¼ 66)
Male 56 (74.7)
Age (yr) 47.8  14.9
BMI (kg/m2) 27.9  4.9
Day 1 Day 21 p
AST (IU/L) 55.3  33.7 41.7  24.5 < 0.001
ALT (IU/L) 81.3  38.5 60.7  36.8 < 0.001
g-GT (IU/L) 122.5  145.7 107.8  208.2 0.243
LDH (IU/L) 223.0  76.0 201.3  39.1 0.035
TB (mg/dL) 0.7  0.2 0.7  0.2 0.292
Cholesterol (mg/dL) 195.6  66.8 182.8  46.7 0.010
ALP (IU/L) 90.3  42.2 87.2  38.0 0.273
Albumin (g/dL) 4.5  0.4 4.6  0.5 0.695
Total protein (g/dL) 7.1  0.5 7.1  0.5 0.842
Glucose (mg/dL) 131.1  67.0 125.3  42.5 0.391
Data are presented as n (%) or mean  SD.
ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate amino-
transferase; BMI, body mass index; LDH, lactate dehydrogenase; TB, total bilirubin;
g-GT, gamma-glutamyl transferase.
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For the measurements of cytokines and adiponectin, serumwas
processed using the TNF alpha human ELISA kit (ab100654; Abcam,
Inc., Cambridge, United Kingdom), the IL-6 human ELISA kit
(ab100572; Abcam, Inc.), and the adiponectin human ELISA kit
(ab99968; Abcam, Inc.). All procedures were performed according
to the manufacturer’s instructions.
2.4. Antioxidant activity
A potentiometric method was used for the calculation of serum
antioxidant activity. The value of antioxidant activity wasmeasured
as the redox potential difference of the K3[Fe(CN6)]/K4[Fe(CN6)]
mediator system using an antioxidant activity measuring device
(IVA Co. Ltd., Yekaterinburg, Russia). Concentrations of antioxidant
activity were calculated using the following equation: antioxidant
activity (ng/mL) ¼ (Cox e aCred)/(1 þ a), where Cox is the con-
centration of the oxidized form of the mediator (mol/L), Cred is the
concentration of the reduced form of the mediator (mol/L); and
a is equal to 10ðE1EÞ=b; where b is equal to 2:3RT=nF , R is the
gas constant, T is the temperature (K), n is the electron number
(n¼ 1), F is the Faraday constant, and E and E1 are the potentials (V)
of the mediator system before and after the addition of the serum,
respectively.
In this study, the standard solution consisted of 0.01M
K3[Fe(CN6)] and 0.1mM K4[Fe(CN6)] in a phosphate buffer solution
(pH 7.2). To measure the redox potential within the solution, a
platinum electrode and an Ag/AgCl electrode were used as the
working electrode and the reference electrode, respectively. First,
the value of E was measured for the 2 mL standard solution. Next,
0.4 mL of serum was added to the standard solution and the new
redox potential E1 was measured. Based on the difference between
E and E1, the value of antioxidant activity was quantitatively esti-
mated using the aforementioned equation [16].
2.5. Fatigue Severity Scale
We used the Krupp Fatigue Severity Scale [17]. The survey had
the following nine questions: (1) mymotivation is lower when I am
fatigued; (2) exercise brings on my fatigue; (3) I am easily fatigued;
(4) fatigue interferes with my physical functioning; (5) fatigue
causes frequent problems for me; (6) my fatigue prevents sustained
physical functioning; (7) fatigue interferes with carrying out certain
duties and responsibilities; (8) fatigue is among my three most
disabling symptoms; and (9) fatigue interferes with my work,
family, or social life. All patients scored each question on a 7-point
scale (1 ¼ strongly disagree, 4 ¼ neither disagree nor agree, and7 ¼ strongly agree). All answers were collected and calculated by
one research nurse in the Department of Internal Medicine.
2.6. Statistical analysis
This study is a clinical trial that evaluated fatigue and other
outcomes in patients with nonalcoholic steatohepatitis. Therefore,
we assumed the sample size by calculating with the difference of
0.7 and standard deviation (SD) of 1 in the fatigue score. A total of
60 patients were needed for this study. The primary outcome was
change in liver enzyme levels and fatigue scale score at 3 wk. The
secondary outcomes were improvement of cytokines, adiponectin,
and antioxidant activities.
All data were expressed as mean  SD unless otherwise stated.
Signiﬁcance was evaluated with a paired t test, independent sam-
ples t test, and analysis of covariance. Statistical signiﬁcance was
observed when p < 0.05. Data obtained from routine blood tests
were analyzed with statistical software (SPSS, version 19.0, SPSS,
Inc., Chicago, IL, USA) and GraphPad Prism version 6.0 for Windows
(GraphPad Software, San Diego, CA, USA).
3. Results
3.1. Patient characteristics
Sixty-six patients (35 patients in the KRG group and 31 in the
placebo group) completed the study. The mean age was 49.4
Table 2
Changes in liver function tests
KRG (n ¼ 35) Placebo (n ¼ 31) p*
Pre Post p Pre Post p
BMI (kg/m2) 26.8  3.8 27.4  4.7 0.610
AST (IU/L) 52.1  30.6 37.3  14.5 0.024 59.1  37.2 47.1  32.2 0.008 0.171
ALT (IU/L) 81.0  43.7 56.9  36.5 0.013 81.6  32.2 65.1  37.2 0.026 0.374
g-GT (IU/L) 106.9  68.6 81.3  56.7 0.012 139.3  198.2 136.4  294.3 0.902 0.574
LDH (IU/L) 226.7  99.0 200.3  35.4 0.135 218.6  34.1 202.5  43.8 0.063 0.748
TB (mg/dL) 0.7  0.2 0.7  0.2 0.939 0.7  0.2 0.6  0.2 0.045 0.081
Cholesterol (mg/dL) 197.4  39.1 186.1  31.4 0.110 193.6  88.2 179.4  59.4 0.043 0.493
ALP (IU/L) 92.2  54.0 86.7  45.2 0.209 88.1  22.2 87.8  28.0 0.925 0.414
Albumin (g/dL) 4.6  0.3 4.7  0.6 0.305 4.5  0.4 4.4  0.4 0.190 0.108
TP (g/dL) 7.1  0.4 7.2  0.5 0.507 7.1  0.6 7.0  0.6 0.240 0.125
Glucose (mg/dL) 125.9  64.5 119.8  39.5 0.470 137.1  70.4 131.6  45.7 0.621 0.399
Data are presented as mean  SD.
* comparison between KRG and placebo.
ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; KRG, Korean Red Ginseng; LDH, lactate dehydrogenase;
TB, total bilirubin; TP, total protein; g-GT, gamma-glutamyl transferase.
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baseline characteristics are outlined in Table 1. Fifty-six patients
(84.9%) had been diagnosed with fatty liver and acute hepatitis. The
mean serum levels of AST, ALT, LDH, and cholesterol were signiﬁ-
cantly decreased after 3 wk (Table 1).
3.2. Blood test
In the KRG group, the mean (from baseline to after 3 wk) levels
of AST (from 52.1 IU/L  30.6 IU/L to 37.3 IU/L  14.5 IU/L), ALT
(from 81.0 IU/L 43.7 IU/L to 56.9 IU/L 36.5 IU/L), and g-GT (from
106.9 IU/L  68.6 IU/L to 81.3 IU/L  56.7 IU/L) improved after KRG
therapy (p < 0.05). However, the levels of LDH, TB, cholesterol, ALP,Table 3
Changes in liver function tests in difference of BMI
BMI  25 k
KRG (n ¼ 24)
Pre Post p
BMI (kg/m2) 28.3  3.1
AST (IU/L) 55.5  35.4 37.9  13.9 0.053
ALT (IU/L) 83.7  47.9 55.8  24.6 0.031
g-GT (IU/L) 112.6  71.2 79.1  63.9 0.024
LDH (IU/L) 233.6  113.8 201.7  35.9 0.192
TB (mg/dL) 0.7  0.2 0.7  0.2 0.827
Cholesterol (mg/dL) 201.3  37.7 183.2  31.8 0.066
ALP (IU/L) 96.3  64.0 86.7  53.4 0.113
Albumin (g/dL) 4.5  0.2 4.6  0.6 0.540
TP (g/dL) 7.1  0.3 7.1  0.4 0.795
Glucose (mg/dL) 126.7  71.1 124.4  43.0 0.843
BMI < 25 k
KRG (n ¼ 11)
Pre Post p
BMI (kg/m2) 22.8  2.6
AST (IU/L) 38.6  5.5 36.1  14.9 0.668
ALT (IU/L) 69.5  23.3 57.3  55.0 0.501
g-GT (IU/L) 97.4  73.4 83.5  47.2 0.236
LDH (IU/L) 220.5  62.2 197.0  40.1 0.393
TB (mg/dL) 0.7  0.3 0.6  0.2 0.413
Cholesterol (mg/dL) 185.0  47.0 182.9  27.1 0.822
ALP (IU/L) 80.9  20.2 87.5  22.1 0.109
Albumin (g/dL) 4.7  0.4 4.9  0.4 0.433
TP (g/dL) 7.2  0.6 7.5  0.6 0.259
Glucose (mg/dL) 129.5  55.7 111.6  33.1 0.124
Data are presented as mean  SD.
* comparison between KRG and placebo.
ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferas
total bilirubin; TP, total protein; g-GT, gamma-glutamyl transferase.albumin, TP, and glucose were not signiﬁcantly different from the
baseline to after 3 wk of KRG therapy (Table 2). Patients with a BMI
of 25 kg/m2 or more who underwent KRG therapy showed partic-
ularly improved mean levels of ALT (from 83.7 IU/L  47.9 IU/L to
55.8 IU/L  24.6 IU/L) and g-GT (from 112.6 IU/L  71.2 IU/L to 79.1
IU/L 63.9 IU/L; p< 0.05). Although patients in the KRG groupwith
a BMI less than 25 kg/m2 did show improved mean levels of ALT
(from 69.5 IU/L  23.3 IU/L to 57.3 IU/L  55.0 IU/L) and g-GT (from
97.4 IU/L  73.4 IU/L to 83.5 IU/L  47.2 IU/L), the differences were
not statistically signiﬁcant (p > 0.05; Table 3).
In the placebo group, the mean levels of AST (from 59.1 IU/
L 37.2 IU/L to 47.1 IU/L 32.2 IU/L) and ALT (from 81.6 IU/L 32.2
IU/L to 65.1 IU/L  37.2 IU/L) improved after placebo therapyg/m2
Placebo (n ¼ 18) p*
Pre Post p
29.8  4.0 0.214
51.4  26.1 48.3  30.7 0.438 0.119
76.6  24.4 70.4  37.8 0.482 0.146
148.3  235.1 166.0  381.9 0.661 0.214
212.8  33.0 207.3  54.2 0.661 0.567
0.7  0.2 0.6  0.2 0.007 0.030
194.1  45.9 180.1  36.3 0.051 0.001
83.7  22.0 87.9  35.3 0.449 0.155
4.6  0.3 4.6  0.4 0.326 0.399
7.2  0.5 7.2  0.4 0.704 0.799
134.8  70.0 125.4  43.9 0.456 0.827
g/m2
Placebo (n ¼ 13) p*
Pre Post p
22.9  1.2 0.965
54.1  25.2 36.8  19.2 0.054 0.519
76.6  36.6 48.6  24.6 0.083 0.593
65.1  49.1 55.9  49.9 0.545 0.645
218.1  28.1 199.1  30.0 0.026 0.897
0.6  0.2 0.7  0.2 0.592 0.585
147.9  47.1 148.8  30.9 0.911 0.067
93.4  27.2 83.9  18.4 0.129 0.059
4.2  0.4 4.2  0.5 0.468 0.057
6.9  0.7 6.6  0.7 0.139 0.037
124.5  33.1 137.1  50.4 0.536 0.168
e; BMI, body mass index; KRG, Korean Red Ginseng; LDH, lactate dehydrogenase; TB,
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glucose did not show signiﬁcant changes after 3 wk. There were
signiﬁcant changes in the levels of TB and cholesterol, but these
were still within the normal range (Table 2).
3.3. Cytokines and adiponectin
The mean IL-6 levels from baseline to after 3 wk changed as
follows: from 2.3 ng/mL  1.9 ng/mL to 1.7 ng/mL  0.7 ng/mL
(p ¼ 0.141) in the KRG group and from 1.5 ng/mL  0.4 ng/mL to 3.8
ng/mL  8.0 ng/mL (p ¼ 0.209) in the placebo group. The two
groups did not show a statistically signiﬁcant difference with re-
gard to the change in IL-6 levels (p ¼ 0.227; Fig. 3).
The mean TNF-a levels from baseline to after 3 wk changed
as follows: from 108.0 pg/mL  54.8 pg/mL to 92.7 pg/mL 
39.0 pg/mL (p ¼ 0.018) in the KRG group and from 123.1 pg/
mL  42.1 pg/mL to 127.5 pg/mL  62.2 pg/mL (p ¼ 0.694) in
the placebo group. There was a signiﬁcant difference in the
change in TNF-a levels between the KRG and placebo groups
(p ¼ 0.031; Fig. 3). The mean TNF-a levels in patients with a BMI
of 25 kg/m2 or more showed particular improvement after KRGFig. 3. Changes in cytokines and adiponectin. There was a signiﬁcant difference in the chang
a and adiponectin levels in patients with a BMI of 25 kg/m2 or more showed particular impro
Ginseng; ns, not signiﬁcant; TNF-a, tumor necrosis factor-a.therapy (116.8 pg/mL  63.7 pg/mL to 92.6 pg/mL  41.6 pg/mL;
p ¼ 0.010). However, in patients with a BMI less than 25 kg/m2
who received KRG therapy, the mean TNF-a levels changed
from 101.1 pg/mL  31.0 pg/mL to 99.5 pg/mL  41.1 pg/mL,
which was not a statistically signiﬁcant change (p ¼ 0.824;
Fig. 3).
The mean adiponectin levels from baseline to after 3 wk
changed as follows: from 7,751.2 pg/mL  3,108.1 pg/mL to 8,197.3
pg/mL  2,714.5 pg/mL (p ¼ 0.109) in the KRG group and from
7,711.6 pg/mL  3,041.3 pg/mL to 7,286.1 pg/mL  5,188.7 pg/mL
(p ¼ 0.717) in the placebo group. There was a signiﬁcant difference
in the change of adiponectin levels between the KRG and placebo
groups (p ¼ 0.027; Fig. 3). This was particularly noticeable in pa-
tients with a BMI of 25 kg/m2 or more, in whom the mean adipo-
nectin levels changed from 7,799.6 pg/mL  3,003.3 pg/mL to
8,326.9 pg/mL  2,445.2 pg/mL (p ¼ 0.186) in the KRG group and
from 6,869.5 pg/mL 2,176.8 pg/mL to 6,306.5 pg/mL 2,052.0 pg/
mL (p ¼ 0.373) in the placebo group. There was a signiﬁcant dif-
ference in the change of adiponectin levels in patients with a BMI of
25 kg/m2 or more within the KRG group from baseline to 3 wk of
treatment (p ¼ 0.017; Fig. 3).e in TNF-a and adiponectin levels between the KRG and placebo groups. The mean TNF-
vement after KRG therapy. BMI, body mass index; IL-6, interleukin-6; KRG, Korean Red
Fig. 4. Changes in antioxidant activity. No statistically signiﬁcant difference in the change of antioxidant activity was observed between the two groups. BMI, body mass index; KRG,
Korean Red Ginseng; ns, not signiﬁcant.
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The mean antioxidant activity from baseline to after 3 wk
changed as follows: from 1.3 ng/mL  0.3 ng/mL to 1.3 ng/mL  0.3
ng/mL (p ¼ 0.467) in the KRG group and from 1.3 ng/mL  0.4 ng/
mL to 1.3 ng/mL  0.4 ng/mL (p ¼ 0.592) in the placebo group. No
statistically signiﬁcant difference in the change of antioxidant ac-
tivity was observed between the two groups (p ¼ 0.916; Fig. 4).
3.5. Fatigue Severity Scale
The mean fatigue scores from baseline to after 3 wk changed as
follows: from 33.0  11.6 to 24.3  8.4 (p< 0.001) in the KRG group
and from 29.8  14.1 to 25.9  12.5 (p ¼ 0.024) in the placebo
group. No statistically signiﬁcant difference was found in the
change of fatigue scores between the two groups (p¼ 0.221; Fig. 5).
In patients with a BMI of 25 kg/m2 or more who received KRG
treatment, the mean fatigue scores showed particular improve-
ment (from 35.0  13.2 to 24.5  8.9; p ¼ 0.003). However, no
signiﬁcant change was observed in patients with a BMI less than 25
kg/m2 in the KRG group, who had mean fatigue scores of 27.3  5.3
at the baseline and 23.1  8.0 at 3 wk (p ¼ 0.166; Fig. 5).
4. Discussion
Our study demonstrated that fatigue severity signiﬁcantly
decreased between Day 0 and Day 21 in both the KRG and placebo
groups. Interestingly, only overweight patients in the KRG group
experienced a more signiﬁcant decrease in their fatigue scores. A
previous report suggested that P. ginseng Meyer is effective inFig. 5. Changes in Fatigue Severity Scale. In patients with a BMI of 25 kg/m2 or more who r
body mass index; KRG, Korean Red Ginseng; ns, not signiﬁcant.treating idiopathic chronic fatigue patients [18]. Until now, how-
ever, no study has assessed the efﬁcacy of P. ginseng Meyer in
treating fatigue in overweight patients. Based on the results of this
study, it is concluded that KRG is effective in treating fatigue in
NAFLD patients, especially in overweight patients.
Outpatients follow-up in this study was performed by one
clinician, who advised the patients to exercise regularly and eat
healthily, and prescribed Legalon (mainly S. marianum) to all pa-
tients. Previously, lifestyle modiﬁcations involving diet and exercise
reduced the body weight of NAFLD patients to 5% [19]. The NAFLD
activity scores improved in 67% of NAFLD patients after 2 yr of
exercise and diet modiﬁcation [20]. S. marianum has been used in
many countries to treat patients with various liver diseases [21,22].
Our study also revealed the improvement in serum biochemical
parameters (AST and ALT) for patients in the placebo group who
received counseling for lifestyle modiﬁcations and Legalon. Taken
together, lifestyle modiﬁcations and S. marianum might be recom-
mended for NAFLD patients for the improvement of hepatitis.
In the KRG group, biochemical parameters such as AST, ALT,
and g-GT were signiﬁcantly decreased after 3 wk of KRG treat-
ment. We found that the decreases in ALT and g-GT levels were
more signiﬁcant in patients with a BMI of 25 kg/m2 or more in the
KRG group than among overweight patients in the placebo group.
Previous research has shown that P. ginseng improves insulin
resistance and decreases ALT levels in rats with liver ﬁbrosis
[23,24]. Other studies have demonstrated that KRG extract de-
creases g-GT levels in rats with alcohol-induced liver damage [25].
Results from previous studies and this study suggest that KRG
alleviates hepatotoxicity, and is especially effective in overweight
patients.eceived KRG treatment, the mean fatigue scores showed particular improvement. BMI,
M. Hong et al / Antifatigue effect of Korean Red Ginseng 209Adiponectin levels are related to metabolic syndrome and fatty
liver disease [26]. Previous research has shown that treating
adipocyte cells with P. ginseng extract increases adiponectin levels
[27]. Similar results were found in studies using mice fed with a
high-fat diet and treated with KRG. Increased adiponectin levels
were observed in the serum of treatedmice that were fed a high-fat
diet [28]. Our study demonstrated that serum adiponectin levels
increased in the KRG group, suggesting that KRG is an effective
treatment for fatty liver disease.
KRG has been recognized as a natural substance with anti-
inﬂammatory effects. Quan et al [29] demonstrated that
streptozotocin-induced diabetic rats treated with 100 mg/kg of KRG
showed lower serum TNF-a levels. Micewith acute liver failure have
increased plasma TNF-a levels, which decrease after treatment with
ginsenoside Rg1 [30]. In addition, it has been shown that ginsan
(isolated from aqueous Korean P. ginseng extract) therapy can reduce
TNF-a levels in healthy volunteers [31]. Based on these results, we
suggest that KRG has signiﬁcant anti-inﬂammatory activity.
It was reported that structures produced by adipocytes are ho-
mologous to adiponectin and TNF-a and are antagonistic to the
insulin-modulating effects of these compounds [26,32]. In this
study, patients with a BMI of 25 kg/m2 ormore showed a signiﬁcant
increase in serum adiponectin levels compared to patients with a
BMI less than 25 kg/m2. In addition, overweight patients treated
with KRG had signiﬁcantly decreased TNF-a levels. In light of these
ﬁndings, we suggest that KRGmay be a useful therapeutic agent for
treating fatty liver disease, especially in overweight patients.
We did not observe changes in the IL-6 level. However, IL-6
levels have been shown to decrease in lipopolysaccharide-treated
THP-1 macrophages treated with Panax notoginseng [33]. Another
study found that P. notoginseng saponins downregulated IL-6 in rats
with liver ﬁbrosis [33]. For the evaluation of exact mechanism of
KRG, more research is required to further investigate the thera-
peutic effect of KRG on IL-6 levels.
One limitation of our study is that we did not obtain a liver bi-
opsy from each patient. Instead, we selected patients who had been
diagnosed with fatty liver and hepatitis by blood tests, a medical
history, and abdominal ultrasound. We followed the clinical prac-
tice guidelines of the Korean Association for the Study of the Liver,
which indicated that NAFLD can be diagnosed by abnormal ﬁndings
on liver function tests, along with a medical history, serological
testing, and abdominal ultrasonography [34].
In conclusion, KRG reduced TNF-a serum levels and increased
adiponectin serum levels in patients with NAFLD. KRG has anti-
inﬂammatory effects, and is especially effective in overweight pa-
tients. Based on these results, we conclude that it is effective to
treat overweight patients with NAFLD with S. marianum, nutrition
and exercise therapy, and KRG.
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